Evidence map›Paper›PMID 38838004›Full record

ArticlePloS one2024

ELISA with recombinant antigen Lb6H validated for the diagnosis of American tegumentary leishmaniasis.

Ruth Tamara Valencia-Portillo, José Angelo Lindoso, Beatriz Julieta Celeste, Amanda Azevedo Bittencourt, Maria Edileuza Felinto de Brito, Malcolm Scott Duthie, Jeffery Guderian, Jorge Guerra, Ana Lúcia Lyrio Oliveira, Steven Reed and 5 more

Abstract readValidation Study
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ruth Tamara Valencia-PortilloFaculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Soroepidemiologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
José Angelo LindosoFaculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Soroepidemiologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
Beatriz Julieta CelesteFaculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Soroepidemiologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
Amanda Azevedo BittencourtInstituto de Infectologia Emílio Ribas, Secretaria de Saúde do Estado de Sao Paulo, Sao Paulo, São Paulo, Brazil.ORCID 0000-0001-5464-2381
Maria Edileuza Felinto de BritoCentro de Pesquisas Aggeu Magalhães, Fundacao Oswaldo Cruz, Recife, Pernambuco, Brazil.
Malcolm Scott DuthieHost Directed Therapeutics, Seattle, Washington, United States of America.
Jeffery GuderianAccess to Advanced Health Institute, Seattle, Washington, United States of America.
Jorge GuerraFundacao de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
Ana Lúcia Lyrio OliveiraFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Steven ReedHost Directed Therapeutics, Seattle, Washington, United States of America.
Mussya Cisotto RochaLaboratório de Investigação Médica (LIM 48), Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.
Nicolle Tayná SantosFundacao de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
Fernando Tobias SilveiraDepartamento de Parasitologia, Instituto Evandro Chagas, Pará, Pará, Brazil.
Hiro GotoFaculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Soroepidemiologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.ORCID 0000-0001-7048-562X
Maria Carmen Arroyo SanchezFaculdade de Medicina, Instituto de Medicina Tropical de Sao Paulo, Laboratório de Soroepidemiologia, Universidade de Sao Paulo, Sao Paulo, São Paulo, Brazil.ORCID 0000-0003-4055-5556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

American tegumentary leishmaniasis (ATL) diagnosis is an open question, and the search for a solution is urgent. The available tests that detect the etiological agent of the infection are specific for ATL diagnosis. However, they present disadvantages, such as low sensitivity and the need for invasive procedures to obtain the samples. Immunological methods (leishmanin skin test and search for anti-Leishmania antibodies) are good alternatives to the etiological diagnosis of ATL. Presently, we face problems with disease confirmation due to the discontinuity in the production of leishmanin skin test antigen, particularly in resource-poor settings. Aiming to diagnose ATL, we validated rLb6H-ELISA for IgG antibodies using 1,091 samples from leishmaniasis patients and healthy controls, divided into four panels, living in 19 Brazilian endemic and non-endemic states. The rLb6H-ELISA showed a sensitivity of 98.6% and a specificity of 100.0%, with the reference panel comprising 70 ATL patient samples and 70 healthy controls. The reproducibility evaluation showed a coefficient of variation of positive samples ≤ 8.20% for repeatability, ≤ 17,97% for reproducibility, and ≤ 8.12% for homogeneity. The plates sensitized with rLb6H were stable at 4°C and -20°C for 180 days and 37°C for seven days, indicating 12 months of validity. In samples of ATL patients from five research and healthcare centers in endemic and non-endemic areas, rLb6H-ELISA showed a sensitivity of 84.0%; no significant statistical difference was observed among the five centers (chi-square test, p = 0.13). In samples of healthy controls from four areas with different endemicity, a specificity of 92.4% was obtained; lower specificity was obtained in a visceral leishmaniasis high endemicity locality (chi-square test, p<0.001). Cross-reactivity was assessed in 166 other disease samples with a positivity of 13.9%. Based on the good diagnostic performance and the reproducibility and stability of the antigen, we suggest using ELISA-rLb6H to diagnose ATL.

Indexed as

Antigens, ProtozoanEnzyme-Linked Immunosorbent AssayLeishmaniasis, CutaneousAdolescentAdultAgedAntibodies, ProtozoanBrazilCase-Control StudiesChildFemaleHumansImmunoglobulin GMaleMiddle AgedRecombinant ProteinsAntibodies, ProtozoanAntigens, ProtozoanImmunoglobulin GRecombinant Proteins

Identifiers

PMID38838004
PMCPMC11152253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.